BRAF: which options do we have for these patients in second line?

5 / 22

BRAF MUTANT CRC: PARTICULARITIES
• <10% responses with BRAF inhibitors in monotherapy1,2
• This poor response seem to provide evidence that biomarker driven approaches
to the treatment of cancer is not enough unless taken with histologic context.
Falchock et al. Lancet 2012, Kopetz et al. J Clin Oncol 2010 Abstr 3524
BASKET CRC cohort
Hyman et al. New Engl J Med 2015
N RR (%)
NSCLC 20 42
Cholangio Ca. 8 13
All others 19 37
ECD/LCH* 26 60
Anapl. Thyroid 7 29
Breast NS -
Ovarian NS -
Myeloma 9 22
Colorectal 10 0